Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

Novel therapies with unique new targets are needed for patients who are relapsed/refractory to current treatments for multiple myeloma. Ibrutinib is a first‐in‐class, once‐daily, oral covalent inhibitor of Bruton tyrosine kinase, which is overexpressed in the myeloma stem cell population. This study...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Richardson, Paul G., Bensinger, William I., Huff, Carol Ann, Costello, Caitlin L., Lendvai, Nikoletta, Berdeja, Jesus G., Anderson, Larry D., Siegel, David S., Lebovic, Daniel, Jagannath, Sundar, Laubach, Jacob P., Stockerl‐Goldstein, Keith E., Kwei, Long, Clow, Fong, Elias, Laurence, Salman, Zeena, Graef, Thorsten, Bilotti, Elizabeth, Vij, Ravi
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Haematological Malignancy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5873373/
https://ncbi.nlm.nih.gov/pubmed/29435979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15058
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados